Inhibrx Biosciences, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: Inhibrx Biosciences Insider Jon Faiz Kayyem Amends 13D Filing, Details Significant Share Acquisitions and Family Transfers
An amended Schedule 13D filing reveals Inhibrx Biosciences insider Jon Faiz Kayyem's increased beneficial ownership to 7.9% through personal funds and family trust transactions, while his family trust's direct ownership dropped below 5%.
NASDAQ
SCHEDULE 13D/A: Inhibrx Biosciences Insider Mark Lappe Boosts Stake to 6.4% Through Recent Share Purchases
Mark Lappe, a key insider at Inhibrx Biosciences, Inc., has increased his beneficial ownership in the company to 6.4% through a series of open-market purchases totaling 164,000 shares between August and September 2024.